---
title: "Oxaliplatin plus 5‑Fluorouracil Induce p53-p21-pRb–Mediated G0/G1 Arrest and Transient Senescence"
id: "biorxiv-8-oxaliplatin-and-5-fluorouracil-induce-p53-p21-prb-associated-cell-cycle-arrest"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-8-oxaliplatin-and-5-fluorouracil-induce-p53-p21-prb-associated-cell-cycle-arrest"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.22.753519v1?rss=1"
published_at: "2026-09-23T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Oxaliplatin plus 5‑Fluorouracil Induce p53-p21-pRb–Mediated G0/G1 Arrest and Transient Senescence
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-8-oxaliplatin-and-5-fluorouracil-induce-p53-p21-prb-associated-cell-cycle-arrest
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.22.753519v1?rss=1)
- **Published At:** 2026-09-23T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study examined effects of **oxaliplatin** combined with **5‑fluorouracil** on patient‑derived low‑grade serous ovarian cancer (**LGSOC**) cells. - Clinically relevant drug concentrations produced minimal cell death but substantially reduced cellular proliferation and clonogenic recovery. - Combined treatment caused robust accumulation of cells in **G0/G1 phase**, indicating cell cycle arrest rather than cytotoxicity. - Treated cells showed increased expression of **p53** and **p21**, and decreased phosphorylation of **pRb**, consistent with activation of the **p53‑p21‑pRb** pathway. - The drug combination induced multiple senescence‑associated features, including increased senescence‑associated β‑galactosidase activity, cellular enlargement and flattening, and higher reactive oxygen species (ROS) production, supporting a **senescence‑like phenotype**. - After drug withdrawal, cells gradually regained proliferative capacity, indicating the senescence‑like state was **transient** rather than irreversibly terminal. - Overall, the findings indicate oxaliplatin plus 5‑fluorouracil primarily cause growth arrest through activation of the p53‑p21‑pRb axis and induce a reversible senescence‑like response in patient‑derived LGSOC cells. - The article is a preprint (bioRxiv) posted September 23, 2026, supported by DxQuest Inc. and the Gerald Bronfman Department of Pathology, McGill University. - Details on precise experimental protocols, sample numbers, and quantitative metrics were not reported in the abstract and would require consulting the full text or supplementary material.
## Clinical Analysis & Structured Key Points
Oxaliplatin and 5-Fluorouracil induce p53-p21-pRb-associated cell cycle arrest and a transient senescence-like phenotype in patient-derived low-grade serous ovarian cancer cells | bioRxiv Skip to main content New Results Oxaliplatin and 5-Fluorouracil induce p53-p21-pRb-associated cell cycle arrest and a transient senescence-like phenotype in patient-derived low-grade serous ovarian cancer cells Rewati Prakash , View ORCID Profile Benjamin Forgie , Alicia A Goyeneche , Edith Zorychta , Abu Noman , Lucy Gilbert , View ORCID Profile Carlos M Telleria doi: https://doi.org/10.64898/2026.09.22.753519 Rewati Prakash 1 McGill University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Benjamin Forgie 1 McGill University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Benjamin Forgie Alicia A Goyeneche 2 McGill University Health Science Centre; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Edith Zorychta 1 McGill University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abu Noman 3 Chittagong University Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lucy Gilbert 1 McGill University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carlos M Telleria 1 McGill University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Carlos M Telleria For correspondence: carlos.telleria{at}mcgill.ca Abstract Info/History Metrics Supplementary material Preview PDF Abstract Objectives Low grade serous ovarian cancer (LGSOC) is characterized by frequent TP53 wild type status and limited responsiveness to conventional chemotherapy. This study investigated the cytotoxic effects of oxaliplatin combined with 5-fluorouracil on patient derived LGSOC cells. Results Clinically relevant concentrations of oxaliplatin and 5-fluorouracil had minimal effects on LGSOC cell viability but markedly reduced cellular proliferation and clonogenic recovery. Combined treatment induced pronounced accumulation of cells in the G0/G1 phase of the cell cycle and increased expression of p53 and p21, accompanied by reduced pRB phosphorylation, consistent with activation of the p53-p21-pRb pathway. Oxaliplatin plus 5-fluorouracil also increased senescence-associated beta-galactosidase activity, cellular enlargement and flattening, and reactive oxygen species production, supporting a senescence-like phenotype. However, after drug withdrawal, treated cells progressively regained proliferative capacity, indicating that the senescence phenotype was transient rather than fully irreversible. Together, these findings show that oxaliplatin plus 5-fluorouracil primarily arrest rather than kill LGSOC cells and induces a transient senescence-like phenotype and G0/G1-phase arrest by activating the p53-p21-pRb pathway. Competing Interest Statement The authors have declared no competing interest. Funder Information Declared DxQuest Inc., North America Gerald Bronfman Department of Pathology, McGill University Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 23, 2026. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Oxaliplatin and 5-Fluorouracil induce p53-p21-pRb-associated cell cycle arrest and a transient senescence-like phenotype in patient-derived low-grade serous ovarian cancer cells Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Oxaliplatin and 5-Fluorouracil induce p53-p21-pRb-associated cell cycle arrest and a transient senescence-like phenotype in patient-derived low-grade serous ovarian cancer cells Rewati Prakash , Benjamin Forgie , Alicia A Goyeneche , Edith Zorychta , Abu Noman , Lucy Gilbert , Carlos M Telleria bioRxiv 2026.09.22.753519; doi: https://doi.org/10.64898/2026.09.22.753519 Share This Article: Copy Citation Tools Oxaliplatin and 5-Fluorouracil induce p53-p21-pRb-associated cell cycle arrest and a transient senescence-like phenotype in patient-derived low-grade serous ovarian cancer cells Rewati Prakash , Benjamin Forgie , Alicia A Goyeneche , Edith Zorychta , Abu Noman , Lucy Gilbert , Carlos M Telleria bioRxiv 2026.09.22.753519; doi: https://doi.org/10.64898/2026.09.22.753519 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (8021) Biochemistry (18781) Bioengineering (14921) Bioinformatics (44492) Biophysics (22625) Cancer Biology (19761) Cell Biology (26945) Clinical Trials (138) Developmental Biology (13993) Ecology (21037) Epidemiology (2067) Evolutionary Biology (25473) Genetics (16185) Genomics (23535) Immunology (18725) Microbiology (42548) Molecular Biology (18095) Neuroscience (93601) Paleontology (701) Pathology (2987) Pharmacology and Toxicology (5104) Physiology (8127) Plant Biology (16020) Scientific Communication and Education (2097) Synthetic Biology (4572) Systems Biology (10251) Zoology (2393)
## Related Clinical Research

- [Artificial intelligence applications for dyspnoea management in advanced lung cancer: scoping revi](https://medichelpline.com/clinical-feed/bmj-open-1-applications-of-artificial-intelligence-in-dyspnoea-management-for-patients.md)
- [WHO publishes country-comparable childhood cancer survival data on WHO data portal](https://medichelpline.com/clinical-feed/who-0-2-country-comparable-childhood-cancer-survival-data-now-available-through-who.md)
- [Symptom network analysis in gastric cancer: tools, core and bridge symptoms, and temporal patterns](https://medichelpline.com/clinical-feed/plos-one-4-application-of-symptom-network-analysis-among-patients-with-gastric-cancer-a.md)
- [Impact of Adjuvant Immune Checkpoint Inhibitors on HRQoL in Renal Cell Carcinoma: Qualitative RAMP](https://medichelpline.com/clinical-feed/plos-one-10-health-related-quality-of-life-with-adjuvant-immune-checkpoint-inhibition-in.md)
- [Vitamin D (VDR/RXR) signaling limits platinum-induced ovarian cancer stem cell plasticity](https://medichelpline.com/clinical-feed/biorxiv-6-activation-of-vitamin-d-signaling-suppresses-platinum-induced-ovarian-cancer.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.